Genetics in the endocrine system: the impact of the TRK family

Troy Hutchens, Mena Mansour

Research output: Contribution to journalReview articlepeer-review


Rearrangements in NTRK are rare actionable oncologic drivers in thyroid carcinoma. Although they only represent a small subset of most thyroid carcinoma subtypes, their identification remains important due to the availability of targeted therapy. Trk inhibitors are currently FDA-approved for NTRK-rearranged cancers independent of primary site and represent a crucial additional therapeutic option for patients with advanced or aggressive thyroid cancer. In the thyroid, NTRK-rearranged cancers have been shown to involve all NTRK family members (NTRK1, NTRK2, and NTRK3) as well as a multitude of different partner genes. Due to their rarity and relatively diverse molecular classification, the clinical and histologic characterization of NTRK-rearranged thyroid carcinoma remains challenging and is not currently well-defined. Given the relatively good prognosis of most thyroid carcinomas, the practical identification of NTRK-rearranged thyroid carcinomas for targeted therapy is case-specific and only considered when current therapeutic options have been exhausted.

Original languageEnglish
Pages (from-to)313-320
Number of pages8
JournalDiagnostic Histopathology
Issue number7
StatePublished - Jul 2022


  • NTRK
  • PTC
  • Papillary thyroid carcinoma
  • Trk
  • thyroid


Dive into the research topics of 'Genetics in the endocrine system: the impact of the TRK family'. Together they form a unique fingerprint.

Cite this